Introduction
============

The insulin-like polypeptide relaxin (RLX), formerly known as a pregnancy hormone \[[@B1]\], has gained interest as a potential humoral mediator in human heart failure \[[@B2]\]. Dschietzig and coworkers \[[@B3]\] have shown that the plasma levels of RLX are increased in relation to the severity of myocardial dysfunction, that the heart is a relevant source of RLX during cardiac failure, and that plasma RLX concentrations are related to left ventricular filling pressures. Comparably, Fisher and coworkers observed high RLX levels in patients with heart failure \[[@B4]\]. In contrast, Kupari and coworkers \[[@B5]\] failed to detect increased plasma RLX levels in patients with aortic valve disease but confirmed that the heart is capable of producing RLX during heart failure states.

Krueger et al. analyzed the effects of physical exercise on plasma RLX levels in patients with heart failure in comparison with healthy controls and observed that plasma RLX levels neither were different between groups nor changed during physical exercise \[[@B6]\]. However, this study investigated a heterogeneous group of heart failure patients including subjects with idiopathic cardiomyopathy as well as patients with ischemic heart disease. Additionally the study did not relate RLX levels to hemodynamics and the plasma concentrations of natriuretic peptides.

The present study was thus designed to determine the effects of physical exercise (bicycle ergometry) on the plasma levels of RLX and N-terminal pro A and B type natriuretic peptides (NTproANP and NTproB-NP, respectively) as established humoral markers for the severity of myocardial dysfunction in a homogeneous group of patients with ischemic heart disease of different severity. Additionally, the relationsship between cardiac power output at maximal charge and the respective hormone levels were analyzed.

Materials and methods
=====================

The investigation conforms with the principles outlined in the Declaration of Helsinki. Following approval by the institutional review board and written informed consent, 40 medical patients with ischemic heart disease were studied during routine right-heart-catheterization (RHC). None of the female patients was at childbearing age. Demographic data are given in Table [1](#T1){ref-type="table"}. Left ventricular ejection fraction was determined echocardiographically before RHC.

###### 

Demographics

  ----------------------------------- -----------------
  Age (years)                         60 (38-78)
  Weight (kg)                         84 (63 - 115)
  Height (cm)                         175 (160 - 190)
  Male/Female                         35/5
  LVEF \[%\]                          47 (20 - 65)
  Diabetes mellitus                   7
  Smoking (Yes/No)                    18/22
  AOD                                 4
  AH                                  32
  Previous MI                         28
  Previous CABG                       19
  Plasma creatinine \[mmol\*l^-1^\]   65(52 - 103)
  ----------------------------------- -----------------

Demographic data and plasma creatinine levels of 40 patients undergoing ergometric exercise testing. Data are median ± range. LVEF: left ventricular ejection fraction (echocardiograpy); AOD: arterial occlusive disease; AH: arterial hypertension; MI: myocardial infarction; CABG: coronary artery bypass grafting.

Patients were studied after overnight fasting. After a 30 min resting period in the supine position a pulmonary artery catheter (Edwards Lifescience, Irvine, USA) was inserted via the brachial vein of the non-dominant arm. Cardiac output was determined by bolus thermodilution. The results are given as the average of three measurements. Arterial blood pressure was determined oscillometrically, heart rate was determined by electrocardiography.

The hemodynamic variables measured were: mean arterial pressure (MAP), cardiac output and index (CO and CI), central venous pressure (CVP), systolic, mean, diastolic and occlusion pulmonary artery pressures (PAPS, PAPM, PAPD, PAOP), and mixed venous saturation (SvO~2~). Peak cardiac power output was calculated as CO × MAP × 0.00222 during maximal charge

Pulmonary arterial blood samples for the determination of RLX, NTproANP, and NTproBNP were drawn from the pulmonary artery. Blood was sampled in EDTA-tubes containing 5000 U aprotinine (Trasylol, Bayer, Germany) and immediately spun for 10 minutes at 3400 rpm. Supernatants were stored at -70°C for further analysis.

After completing the baseline measurements (t1), the patients performed an ergometric test in the supine position. Starting with 25 watt, charge was increased in 25 to 100 watt steps every sixth minute according to the estimated capacity of the patient. Repeated measurements were performed during each step test for a maximum of 3 steps (t2, t3, t4). Maximal charge varied from 25 to 200 watts depending on the achievement of stop criteria.

Stop criteria were: achievement of submaximal heart rate (200 bpm minus age), missing increase of heart rate during charge, arterial blood pressure \> 240/120 mmHg, PAOP \> 40 mmHg, PAPM \> 60 mmHg, SvO~2~\< 40%, ST-lowering \> 0,2 mV, a decrease in arterial blood pressure during charge, angina pectoris, shortness of breath, peripheral exhaustion, and recurrent ventricular arrhythmias despite of repositioning the PA-catheter.

Ischemia during ergometric testing was defined as angina pectoris combined with typical electrocardiographic signs of myocardial ischemia and/or a sudden increase in PAOP of more than 20 mmHg.

After a resting period of 10 minutes a blood analyses was drawn for determination of recovery hormone levels (t5).

Determination of Relaxin
------------------------

RLX was determined by a sandwich-type enzyme immunoassay (EIA) as described previously \[[@B7]\]. Shortly, this assay is based on two specific polyclonal antibodies raised in rabbits against recombinant human gene H2-RLX. The detection limit of this assay is 1.2 pg\*ml-1. The standard range is 1.2 to 250 pg\*ml^-1^. Recovery in plasma is 97 ± 4.5%. The intra-assay coefficient of variance at 15.3 pg \* ml^-1^was 9.6% (n = 18), the inter-assay coefficient of variance at 15.6 pg \* ml^-1^was 10.2% (n = 12). The assay has a cross-reactivity of less than 0.01% with insulin, insulin-like growth factor, LH, and FSH.

Determination of NT proANP
--------------------------

NTproANP was determined by a competitive-binding radioimmunoassay with magnetic solid phase technique in a modification of Sundsfjord et al. \[[@B8]\] using the same rabbit-anti-rat proANP polyclonal serum, human proANP (1-30) from Peninsula Lab (Bachem Ltd, St. Helene, UK)asthe standard, and iodined proANP 1-30 purified by HPLC for radiolabeling. In order to achive high sensitivity and good precision, Dynabeads M280 with sheep-anti-rabbit IgG (Dynal Biotech, Oslo, Norway) as solid phase and second antibody were used. The coefficient of variance at 425, 1163, and 2490 pmol \* l^-1^was 7.5, 3.7, and 3.4%, respectively. The detection limit was 30 pmol/l.

Determination of Nt probNP
--------------------------

NTproBNP was determined by an electrochemoluminescence immunoassay (Elecsys proBNP sandwich immunoassay; Roche Diagnostics, Basel, Switzerland) on Elecsys 2010 \[[@B9]\]. The mean intraassay variance was 4.3% (range: 2.7 to 5.9% for plasma samples with a concentration between 7.6 to 2732 pmol \* l^-1^with an interassay variance of 3.2%). The lower detection limit was 0.6 pmol \* l^-1^.

Statistical analyses
--------------------

Following the observation that only 23 of the patients were capable of performing all exercise steps and that 8 patients achieved the stop criteria already during exercise step 1, peak charge levels for hemodynamic and hormonal parameters were used for further analysis to achieve comparability between individuals.

After the ergometric testing, patients were grouped according to peak cardiac power output. As suggested by Williams and coworkers \[[@B10]\], a cut-off value \< 1.96 watt was used to divide the patients in groups of high degree (HDHF: n = 18) and low degree heart failure (LDHF: n = 22).

Data are given as median ± range. With respect to the high variability of baseline hormone levels, data were analyzed non-parametrically. Friedman\' test followed by Wilcoxon\'s matched pairs test was used for intra-individual comparisons. Mann-Whitney U test was applied for analyses of differences between the HDHF and the LDHF group. Fisher\' s exact test was used to analyze between group differences of nominal variables. Correlation analyses were performed by Spearman\'s rank correlation test. A p-value of less than 0.05 indicates statistical significance; p = n.s. denotes no statistical significance.

Results
=======

All patients underwent successful ergometric testing. No complications related to the right heart catheterization occurred. Five patients in the HDHF group but none in LDHF were tested postive for myocardial ischemia (p = 0.013).

Hemodynamics
------------

The course of hemodynamics is given in Table [2](#T2){ref-type="table"}, showing that exercise was associated with profound changes in cardiac index, mean arterial pressure, mixed venous saturation and filling pressures. Peak cardiac power output (CPO) at the individual maximal charge was 2.7 (1.2 - 5.5) W.

###### 

Hemodynamics

                   t1          t2          t3          t4
  ---------------- ----------- ----------- ----------- -----------
  **CI**           2.9         3.4\*       4.6\*       6.3\*
  \[l/min/m^2^\]   (1.4-4.4)   (2.5-5.3)   (3.1-7.2)   (4.3-9.4)
  **MAP**          92          112\*       112\*       121\*
  \[mmHg\]         (75-126)    (83-116)    (95-114)    (100-140)
  **HR**           68          88\*        105\*       122\*
  \[bpm\]          (44-95)     (62-114)    (70-134)    (102-173)
  **SvO~2~**       66          41\*        36\*        32\*
  \[%\]            (58-75)     (27-58)     (21-55)     (20-49)
  **CVP**          4           16          9           9\*
  \[mmHg\]         (2-12)      (7-26)      (8-11)      (4-15)
  **PAPM**         15          34\*        36\*        36\*
  \[mmHg\]         (10-36)     (15-65)     (21-52)     (22-56)
  **PAOP**         8           20\*        20\*        23\*
  \[mmHg\]         (4-28)      (9-43)      (8-35)      (7-39)

The course of hemodynamics in 40 patients with ischemic heart disease undergoing ergometric bicycle testing. t1: Baseline after 30 min rest; t2 to t4: ergometric testing with increasing charges. CI: cardiac index; MAP: mean arterial blood pressure, HR: heart rate; SvO~2~: mixed venous oxygen saturation; CVP: central venous pressure; PAPM: mean pulmonary artery pressure; PAOP: pulmonary artery occlusion pressure. \*: significant difference (p \< 0.05) in comparison with t1 (Friedman\'s test followed by Wilcoxon\'s matched pairs test).

Analysis of between group differences in the HDHF and the LDHF groups revealed that the HDHF group (peak CPO: 1.46 (1.04-1.86) W) had higher baseline pulmonary artery pressures (data not shown) and PAOP levels (10 (4-28) vs. 6 (4-14) mmHg, p = 0.03), a lower baseline SvO~2~(63 (58-73) vs. 69 (63-75) %, p = 0.002), higher peak exercise PAOP (31 (13-43) vs. 23 (7-35) mmHg, p = 0.005) but lower MAP (111 (98-126) vs. 122 (100-142) mmHg, p = 0.02) and CI (3.6 (2.7-4.8) vs. 6.3 (4.3-9.4), p \< 0.0001) than the LDHF group.

Differences in demographics and medication in both groups is given in Table [3](#T3){ref-type="table"}, showing that patients in the HDHF group were more frequently tested positively for ischemia during exercise and were more frequently treated with digitalis.

###### 

Demographic data and medication in the LDHF and HDHF groups

                                       LDHF (n = 22)     HDHF (n = 18)   **sign**.
  ----------------------- ------------ ----------------- --------------- ------------
  Age (years)                          59 (38-64)        60 (39-78)      n.s.
  Weight (kg)                          86 (70 - 115)     82 (63-91)      n.s.
  Height (cm)                          180 (160 - 190)   172 (160-185)   n.s.
  Male/Female                          21/1              14/4            n.s.
  LVEF \[%\]                           60 (20 - 65)      45 (30 - 60)    n.s.
  Previous MI             \[yes/no\]   18/4              10/8            n.s.
  Previous CABG           \[yes/no\]   10/22             9/18            n.s
  Previous PCI            \[yes/no\]   11/22             10/18           n.s.
  Pos. ischemia testing   \[yes/no\]   0/22              5/13            p = 0.013
  Duration of IHD         \[months\]   1 (1-50)          2 (1 - 120)     n.s.
  Betablocker             \[yes/no\]   22/0              18/0            n.s.
  ACE-inhibitor/ARB       \[yes/no\]   17/5              17/1            n.s.
  Diuretics               \[yes/no\]   5/17              9/9             (p = 0.08)
  Aldosterone-Blocker     \[yes/no\]   0/22              1/17            n.s.
  Digitalis               \[yes/no\]   2/20              7/11            p = 0.025

Demographic data and medication of patients with ischemic heart disease (IHD) grouped according to the results of ergometric exercise testing in a high degree heart failure (HDHF) and a low degree heart failure group (LDHF). Data are median ± range. LVEF: left ventricular ejection fraction (echocardiograpy); MI: myocardial infarction; CABG: coronary artery bypass grafting; PCI: percutaneus coronary intervention; positive ischemia testing: please see text for details; ARB: angiotensin receptor blocker. p \< 0.05: significant between group difference (continuous data: Mann-Whitney U, nominal data: Fisher\'s exact test).

Hormones
--------

The course of NTproANP, NTproBNP and RLX in all patients is given in Figure [1](#F1){ref-type="fig"}, showing that both natriuretic peptides increased modestly during maximal charge and recovery and that RLX levels during recovery were significantly lower than baseline levels.

![**The course of the plasma levels of the N-terminal prohormones of the A-and B-type natriuretic peptides (NTproANP, NTproBNP) and relaxin (RLX) in patients with ischemic heart disease undergoing physical exercise testing**. Baseline: after 30 min supine rest; max. charge: during peak exercise; recovery: 10 min after peak exercise. Data are given as box blots. P-values denote a significant difference versus baseline (Friedman\'s test followed by Wilcoxon\'s matched pairs test).](2047-783X-14-3-106-1){#F1}

The course of hormones in the HDHF and the LDHF groups is depicted in Figure [2](#F2){ref-type="fig"}, showing that plasma NTproANP and NTproBNP levels were higher and RLX levels were lower in the HDHF in comparison with the LDHF group. NTproANP and NTproBNP in the EDHF and the LDHF increased comparably to the changes observed in all patients (Figure [2](#F2){ref-type="fig"}) while no significant changes in plasma RLX were observed.

![**The course of the plasma levels of the N-terminal prohormones of the A-and B-type natriuretic peptides (NTproANP, NTproBNP) and relaxin (RLX) in patients with ischemic heart disease undergoing ergometric exercise testing grouped according to peak cardiac power output (CPO) less or greater than 1.96 W**. Baseline: after 30 min supine rest; max. charge: during peak exercise; recovery: 10 min after peak exercise. High degree heart failure (open box plots: peak CPO \< 1.96 W; n = 18); low degree heart failure (grey box plots: CPO \> 1.96 W; n = 22). P-values denote significant differences between groups (Mann-Whitney -U test). Friedman\'s test followed by Wilcoxon\'s matched pairs test revealed significant within group changes in NTproANP and NTproBNP levels and no significant changes in plasma RLX.](2047-783X-14-3-106-2){#F2}

Individual changes in RLX levels in the HDHF and LDHF group are given in Figure [3a](#F3){ref-type="fig"}. and 3.b, showing a high variability at baseline and heterogenous responses during exercise and recovery in both groups. From baseline to recovery RLX increased in 8 and decreased in 10 patients in the HDHF-group and increased in 14 but decreased in 8 patients in the LDHF-group.

![**The individual changes in plasma relaxin (RLX) levels in patients with ischemic heart disease undergoing ergometric exercise testing grouped according to peak cardiac power output (CPO) less or greater than 1.96 W**. Baseline: after 30 min supine rest; max. charge: during peak exercise; recovery: 10 min after peak exercise. a. high degree heart failure (peak CPO \< 1.96 W; n = 18); b. low degree heart failure (CPO \> 1.96 W; n = 22). Friedman\'s test followed by Wilcoxon\'s matched pairs test revealed no significant within group changes. Please note the different scales on the y-axes.](2047-783X-14-3-106-3){#F3}

Correlation Analyses
--------------------

Correlation analyses revealed no correlation between RLX baseline plasma levels and corresponding hemodynamic indices and the EF. Inverse correlations between RLX levels and NTproANP (Spearman\'s rho (r/R) = -0.33, p = 0.047) and NTproBNP (r/R = -0.41, p = 0.013) were observed. The correlation between RLX baseline levels and peak CPO was r/R = 0.48 (p = 0.0056).

In contrast, NTproANP and NTproBNP baseline levels were strongly to moderately associated with hemodynamic parameters at rest (NTproANP vs: EF: r/R = -0.36 (p = 0.02); PAPS: r/R = 0.72 (p \< 0.0001); PAPD: r/R = 0.67 (p \< 0.0001); PAPM: r/R = 0.66 (p \< 0.0001); PAOP: r/R = 0.71 (p \< 0.0001); SvO~2~: r/R = -0.47 (p = 0.0045); NTproBNP vs: EF: r/R = -0.52 (p = 0.008); PAPS: r/R = 0.53 (p = 0.0016); PAPD: r/R = 0.48 (p = 0.004); PAPM: r/R = 0.48 (p = 0.0038); PAOP: r/R = 0.51 (p = 0.0021); SvO~2~: r/R = -0.38 (p = 0.02)). The correlation between NTproANP and NTproBNP baseline levels and peak CPO was r/R = -0.55 (p = 0.0045) and r/R = -0.66 (p \< 0.0001), respectively.

Only minor correlations were observed between hemodynamics changes from baseline to maximal charge and changes in RLX and NTproANP (delta MAP vs. delta RLX: r/R = 0.35 (p = 0.046); delta NTproANP vs. delta PAOP: r/R = 0.39 (p = 0.0025); delta NTproANP vs. delta SVI: r/R = -0.35 (p = 0.044); delta NTproANP vs. delta proBNP: r/R = 0.39 (p = 0.027)).

Discussion
==========

Recently, Dschietzig el al. suggested that the polypeptide RLX is \"an important player in heart failure\" \[[@B3]\]. This assumption was based on the observation that the heart is a RLX net producer in heart failure states and that the plasma levels of RLX in a study in patients presenting with acute cardiac decompensation were closely related to left ventricular filling pressures and the clinical severity of myocardial dysfunction. Additionally this group showed that RLX is a functional antagonist of the vasoconstrictory effects of endothelin-1; suggesting that the increase of RLX in heart failure may be a compensatory response \[[@B2]\]. However, data from other groups on the role of RLX in heart failure are controversial. Fisher and coworkers reported that increased plasma RLX levels in heart failure patients have no prognostic relevance and failed to detect a meaningful correlation between this hormone an NTproBNP as an accepted humoral marker of myocardial dysfunction \[[@B4]\]. Comparably, Kupari and coworkers did not detect any correlation between plasma RLX levels and \"any measure of cardiac structure or function\" in a group of patients with isolated aortic valve disease \[[@B5]\], and Krüger et al. \[[@B6]\] did not observe any difference in RLX levels at baseline as well as at peak exercise in compensated heart failure patients compared to a healthy control group. Thus obviousy the RLX impact in the setting of human heart failure has not been satisfactorily solved.

Right heart catherization with ergometric testing is an established method for the quantification of cardiac dysfunction under different loading conditions. Besides conventional hemodynamic parameters (cardiac index and filling pressures) that may be used for quantification of cardiac function, peak cardiac power output - the product of cardiac output and mean arterial blood pressure - is a measure of myocardial dysfunction of prognostic relevance \[[@B10]\] which integrates cardiac output and ventricular afterload \[[@B11]\].

The results of our study question the role of plasmatic RLX as a compensatory humoral mediator in human heart failure: We neither did observe any direct correlation between plasma RLX and hemodynamic function at rest nor a positive correlation with NTproANP or NTproBNP baseline levels. In contrast, inverse correlations between RLX levels and natriuretic peptides at baseline and a positive correlation between RLX and peak CPO were detected. Additionally, RLX levels tended to decrease during exercise and decreased during recovery during exercise (in the whole group), showed a highly variable and inhomogeneous response pattern in the HDHF and the LDHF group, and were lower in patients with more severe myocardial dysfunction. It is of note that we have recently shown that plasma RLX levels in healthy volunteers were higher than those reported by Dschietzig and coworkers for patients with severe myocardial failure \[[@B7]\].

It remains to be determined how the discrepancies between the above mentioned studies can be explained; even taking into account that Dschietzigs patients were in acute heart failure while the patients in the other studies were performed in stable patients with either chronic heart failure \[[@B4]-[@B6]\] or as in the present study in patients with ischemic heart disease and varying degree of myocardial dysfunction. Interestingly, patients in the HDHF group were more frequently tested positive for ischemia during exercise. The neurohumoral response in these patients may thus -at least in part -be more intensively influenced by myocardial ischemia than by myocardial failure. However, plasma levels of RLX were not significantly different between patients with or without ischemia during the study period (data not shown). Comparably, patients in the HDHF were more frequently treated with digitalis and as a trend (p = 0.08) more frequently with diuretics. Since no data are available on the effects of acute myocardial ischemia, digitalis, and diuretics on plasma levels of RLX any attempt to explain the findings of the present study on the basis of these differences remains speculative.

It is of note that the immunoassay kit in all studies mentioned so far was purchased from the same manufacturer. In contrast to Dschietzig and coworkers (personal communication), we added aprotinine during blood sampling to prevent protein degradation. This, however, may explain absolut differences in RLX levels between both studies but does not help to explain the lack of relative differences, i.e the fact that patients with more severe myocardial dysfunction had lower RLX levels. Consequently, variations in laboratory technology are not helpful in explaining the contradictory results between Dschietzigs \[[@B3]\] and our findings. It is of note that the analyses in the present study were performed in the reference laboratory of the manufacturer (Immundiagnostik AG), rendering possible errors in the analytical technique rather unlikely.

With respect to the pleiotropic effects of RLX, several alternative explanations for these discordant results may be conceivable. For example, plasma RLX levels have been shown to be related to insulin sensitivity and serum fibrinogen levels in female patients with type 2 diabetes mellitus \[[@B12],[@B13]\], suggesting, that this „\"insulin-like\" hormone is indeed related to changes in metabolism.

Additionally, a lack of systemic changes in RLX levels does not exclude effects of this hormone on the organ or cellular levels. This may be derived from the observation that acute volume loading in healthy volunteers leads to a significant increase in urinary excretion of RLX despite unchanged plasma RLX levels \[[@B7]\]. Variable results have been reported on the role of RLX as a paracrine humoral mediator in the cardiovascular system. In a very recent publication, Dschietzig an coworkers have shown upregulation of RLX mRNA-transcription and RLX protein content in the left atria and ventricles of spontaneous hypertensive rats in comparison with nonhypertensive Wistar Kyoto rats and a close inverse correlation between left atrial and ventricular relative myocardial mass and the RLX protein content \[[@B14]\], suggesting that this peptide may exert antihypertrophic effects in this model of increased vascular resistance. It is not known, if RLX may have comparable effects in humans.

In contrast to RLX, NTproANP and NTproBNP were highly accurate in differentiating between patients with less and more severe myocardial dysfunction, either in the resting state as well as during exercise. This supports the well established role of these hormones for the detection of myocardial failure \[[@B9]\].

Few data is available about the course of NTproB-NP during physical exercise and no data exists about NTproANP. Scharhag et al. observed that NTproBNP increased after a walking test in patients with IHD and that patients with more severe myocardial dysfunction showed a more pronounced increase of this hormone 30 min after exercise. In contrast to our data, no correlation between NTproBNP baseline levels and peak cardiac power output was observed \[[@B15]\]. The changes in NTproANP levels were less pronounced as it has been shown for the active compound ANP \[[@B16]\]. This may be explained by the different plasma half-lifes and the higher plasma levels of the N-terminal prohormones in comparison with the active hormones.

In summary, the data presented in this study clearly shows that patients with ischemic heart disease and myocardial dysfunction -diagnosed by invasive hemodynamic parameters - present with lower levels of plasma relaxin than patients with preserved myocardial function and that plasma RLX levels are inversely related to the severity of heart disease in these patients. Therefore, in our opinion, the significance of RLX as an important compensatory hormone in IHD patients has not been clearly answered so far.

Acknowledgements
================

We acknowledge the help of Charlotte Neubert from Immundiagnostik AG, Bensheim, Germany and Ragnhild Wergeland, MD, Institute of Clinical Biochemistry, Rikshospitalet, University of Oslo, Norway for performing the hormone analyses. We thank Roche Diagnostics, Germany, for providing the kits for determination of NTproANP and NTproBNP. We also appreciate the great amount of effort of our institutional statistician Michael Hüppe, PhD, when supporting our study.

Declaration of a potential conflict of interest
-----------------------------------------------

The authors Matthias Heringlake and Frank Eberhardt have received scientific support by Roche Diagnostics, Germany. Franz-Paul Armbruster is the director of Immundiagnostik AG, the manufacturer of the relaxin assay.
